About us Contacts Drug interactions: 390 212
Drug search by name

Darunavir Tablets and Yupelri

Determining the interaction of Darunavir Tablets and Yupelri and the possibility of their joint administration.

Check result:
Darunavir Tablets <> Yupelri
Relevance: 17.05.2023 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Darunavir may increase the blood levels of revefenacin following oral inhalation. This may increase side effects such as drowsiness, blurred vision, dry mouth, heat intolerance, flushing, decreased sweating, difficulty urinating, abdominal cramping, constipation, rapid heart beat, confusion, memory problems, and glaucoma. Although serious side effects are not very common with inhaled products such as revefenacin because only limited amounts of the medication generally get absorbed into the bloodstream from the lungs, they can sometimes occur, especially in the elderly or when combined with medications that can impair its clearance from the body. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact. You should avoid activities requiring mental alertness such as driving or operating hazardous machinery until you know how these medications affect you. Also keep your eyes closed or use an eye mask during inhalation to avoid having the medication get into the eyes, which can cause blurry vision and eye pain as well as increase absorption of the medication into the bloodstream. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

GENERALLY AVOID: Coadministration of revefenacin with inhibitors of organic anion transporting polypeptide (OATP) 1B1 and/or 1B3 may increase systemic exposure to its active metabolite, which has been reported to be a substrate of the hepatic uptake transporters. No pharmacokinetic data are available, but increased anticholinergic adverse effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) may occur. In study patients, revefenacin was rapidly converted to its active metabolite following inhaled administration, and plasma exposures of the metabolite exceeded those of revefenacin by approximately 4- to 6-fold. The activity of the metabolite at target muscarinic receptors is approximately one-third to one-tenth that of revefenacin and could potentially contribute to systemic antimuscarinic effects at therapeutic doses.

MANAGEMENT: Concomitant use of revefenacin with OATP 1B1 and/or 1B3 inhibitors is not recommended.

References
  • "Product Information. Yupelri (revefenacin)." Mylan Specialty, Morgantown, WV.
Darunavir Tablets

Generic Name: darunavir

Brand name: Prezista

Synonyms: Darunavir

Yupelri

Generic Name: revefenacin

Brand name: Yupelri

Synonyms: Yupelri Inhalation

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

Interaction with food and lifestyle
Disease interaction